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INTRODUCTION 
Parkinson’s  Disease is  one of  the most  debi l i ta t ing neurological  
diseases  with a  profound effect  on qual i ty  of  l i fe .  The motor  
components  of  Parkinson’s  disease have been wel l  documented 
and extensively s tudied.  Most  of  the t reatment  of  Parkinson’s  
disease has  been aimed at  the management  of  motor  
complicat ions with a  view to improving qual i ty  of  l i fe .  
However  in  advanced s tages  of  Parkinson’s ,  the  manifestat ion 
of  non-motor  symptoms becomes much more apparent  and their  
management  gains  prominence.  
Pain is  one of  the recognised non-motor  symptoms of  
Parkinson’s  Disease.  However  not  much research has  been done 
into def ini t ively def ining pain in  Parkinson’s  or  i ts  
management .  Keeping in  mind the debi l i ta t ing potent ia l  of  pain 
by i tself ,  i t  needs more extensive research to  def ine the severi ty  
of  pain and i ts  presentat ion in  Parkinson’s  Disease.   
Keeping in  mind the i r revers ible  nature  of  Parkinson’s  disease 
and the improved t reatment  of  the disease in  the community 
owing to  bet ter  heal thcare  coverage,  more and more pat ients  are  
now surviving into the advanced s tages  of  Parkinson’s  Disease.  
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Hence the management  of  non-motor  complicat ions is  gaining 
importance.  
In  this  s tudy we at tempt  to  s tudy the prevalence of  pain in  
pat ients  with Parkinson’s  Disease along with the epidemiology 
and def ine the severi ty  and the type of  pain.  We also look at  the 
relat ionship of  the pain to  the Parkinsonian t reatment  and the 
response to  the same.  
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AIMS AND  
OBJECTIVES  
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AIMS AND OBJECTIVES 
1. To a n a l y s e t h e p r e v a l e n c e o f  p a i n i n  p a t i e n t s  w i t h 
Parkinson’s  Disease 
2.  To analyse the type and severi ty  of  pain when present  in  
Parkinson’s       
    Disease  
3 .  To look into the correlat ion of  pain with s tage of  the disease  
4 .  To look into the correlat ion of  pain with durat ion of  disease.  
5 .  To analyse the correlat ion of  pain with drugs and the 
response to                
    Parkinson’s  t reatment  
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  REVIEW OF LITERATURE  
SOURCE OF LITERATURE 
The l i terature  source for  review of  our  s tudy was taken from 
p u b l i s h e d s t u d i e s  d e s c r i b i n g t h e p r e v a l e n c e o f  p a i n ,  
character is t ics  of  pain and i ts  response to  t reatment .  Pr ior i ty  
was given to  more recent  s tudies  and older  s tudies  were used 
when no other  data  was avai lable ,  Art ic les  publ ished in  Engl ish 
were only used.  Medline and Movement  Disorder  Society were 
the main electronic  data  used for  the l i terature  review.  
Since there  is  a  pauci ty  of  Indian s tudies  on the subject ,  most  
of  the l i terature  is  based on Western s tudies .  The aim of  the 
l i terature  review was to  f i l l  the  gaps in  knowledge regarding 
pain in  PD.  The main l imitat ions were lack of  convincing 
s tudies  f rom India  regarding pain in  Parkinson’s  Disease and i ts  
character is t ics .  
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PATHOPHYSIOLOGY OF PARKINSON’S 
DISEASE 
Parkinsonism is  a  syndrome descr ibed by a  combinat ion of  any 
o f  t h e s i x  f o l l o w i n g c a r d i n a l  f e a t u r e s ,  t r e m o r a t  r e s t ,  
bradykinesia ,  r igidi ty,  loss  of  postural  ref lexes ,  f lexed posture  
and freezing.  A combinat ion of  the symptoms are  used to  def ine 
def ini te ,  probable  and possible  parkinsonism.  The most  common 
cause is  idiopathic  and is  known as  Parkinson’s  Disease.  The 
cl inical  complex was f i rs t  descr ibed by James Parkinson in  
1817.  Parkinson’s  Disease was ear l ier  referred to  as  “paralyt ic  
agi tans” and “maladie  de Parkinson” by Charcot . 1  
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Fig 1.  Parkinsonism Diagnostic  Criteria 1
Park inson ’s  D i sease i s  i d iopa th i c  and i s  a  d i agnos i s  o f  
exclusion.  The cl inical  diagnosis  is  made using the United 
Kingdom Parkinson’s  Disease Socie ty(UKPDS) Brain Bank 
Cri ter ia  or  the recent  Movement  Disorder  Society-  Parkinson’s  
Disease Cri ter ia  (MDS-PD).   
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Fig 2.  UKPDS Brain Bank criteria for PD
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Fig 3.  MDS- PD cl inical  criteria 2
ANATOMICAL PATHOLOGY  
The main s i te  of  pathology in  PD is  the basal  gangl ia ,  pr imari ly  
the substant ia  nigra  compacta  (SNC).  SN shows depigmentat ion,  
loss  of  nerve cel ls  and gl iosis .  Other  common si tes  involved in  
the brain are  the locus ceruleus and the raphe nuclei .  All  these 
cel ls  a lso show depigmentat ion as  wel l .  Lewy bodies  have been 
descr ibed as  the pr imary pathological  hal lmark of  PD.  They 
have been found also in  the per ipheral  nervous system and the 
central  nervous system, including the cerebral  cor tex,  dorsal  
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Fig.4.  Lewy Bodies3
motor  vagal  nucleus,  hypothalamus,  nucleus basal is  of  Meynert  
and sympathet ic  gangl ia .  
The presence of  Lewy Bodies  helps  different ia te  PD from 
P a r k i n s o n ’ s  P l u s  s y n d r o m e s a n d p o s t - e n c e p h a l i t i c  
Parkinsonism.  However  some of  the forms of  juveni le  PD and 
mutat ions of  parkin and LRRK2 genes are  except ions,  with 
absence of  Lewy Bodies .   
Lewy bodies  consis t  of  a  dense inner  core surrounded by a  
radiat ing f i lamentous outer  zone.  1 
BIOCHEMICAL PATHOLOGY 
Loss of  dopamine in  the basal  gangl ia  has  been def ined as  the 
p r i m a r y b i o c h e m i c a l  a l t e r a t i o n i n  t h e p a t i e n t  w i t h P D . 
Dopamine rg ic  neu rons p ro j ec t  f rom the Subs t an t i a  N ig ra 
compacta  to  the neostr ia tum and from the ventral  tegmental  
a rea to  the l imbic sys tem and neocor tex .  PD spares  the 
mesol imbic and mesocort ical  neurons.  The nigrostr ia ta l  neurons 
a r e  p rog re s s ive ly l o s t .  Pos t e r io r  s t r i a tum, e spec i a l l y  t he 
putamen,  is  the ear l ies t  s i te  involved.  This  can be picked up 
ear l ies t  on FDOPA PET scans.  
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PD also has  loss  of  other  monoaminergic  neurons containing 
norepinephrine and serotonin.  However  this  is  to  a  lesser  extent  
than dopamine.  Dopamine loss  accounts  for  most  of  the motor  
symptoms whereas  the non motor  symptoms are  acoounted for  
by loss  of  other  neurotransmit ters ,  including acetylchol ine 
which is  decreased in  the thalamus.  This  loss  of  neurons leads 
to  hyper sen t iv i ty  to  the neuro t ransmi t t e r  wh ich l eads to  
compensat ion of  symptoms in  ear ly  def ic iency.  The symptoms 
of  PD manifest  only when there  is  an 80% reduct ion in  
dopamine in  the putamen which corresponds to  a  60% loss  of  
nigrostr ia ta l  dopaminergic  neurons.  
 20
Fig.5.  Pathways of  Basal  Ganglia 4
The loss  of  dopaminergic  neurons of  the Substant ia  Nigra 
compacta  is  highly correlated to  the motor  symptoms of  PD.  
Other  symtpoms are  not  as  wel l  correla ted to  a  specif ic  
monoaminergic  neruron or  neurotransmit ter.   
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ETIOPATHOGENESIS 
Mult iple  mechanisms of  neuronal  damage have been proposed in  
P a r k i n s o n ’ s  D i s e a s e .  o x i d a t i v e s t r e s s ,  m i t o c h o n d r i a l  
dysfunct ion,  exci totoxici ty,  inf lammation and apoptosis .  Toxic  
protein accumulat ion,  in  the form of  Lewy bodies  and neuri tes ,  
has  been proposed recent ly  to  be the major  pathogenic  factor  a t  
play.  Toxic  protein accumulat ion can be a  consequence of  e i ther  
impaired degradat ion or  excessive synthesis  that  saturates  the 
degradat ion mechanism.  
Oxidat ive s t ress  occurs  due to  monoamine metabol ism and auto-
oxidat ion.  Reduced glutathione has  been found consis tent ly  in  
PD at  post  mortem. However  there  is  s t i l l  debate  whether  the 
reduced glutathione is  e i ther  a  cause or  resul t  of  excess  
oxidat ive s t ress .  Neuromelanin is  proposed to  be protect ive 
against  oxidat ive s t ress .  I ron accumulat ion has  been proposed 
to  accumulate  to  oxidat ive s t ress .  Uric  acid,  an endogenous 
ant ioxidant ,  has  been found to  protect  against  the progression 
of  PD.  This  has  lent  credence to  the oxidat ive s t ress  theory of  
Parkinson’s  Disease.  
Mitochondrion dysfunct ion is  another  important  mechanism that  
is  suggested in  the pathogenesis  of  Parkinson’s  Disease.  1-
m e t h y l - 4 - p h e n y l - 1 , 2 , 3 , 6 -  t e t r a h y d r o p y r i d i n e ( M P T P ) 
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in tox ica t ion causes  impa i rment  o f  Complex I  ac t iv i ty  in  
mitochondrion and dopamine neuron destruct ion.  Rotenone is  
another  Complex I  toxin which can cause PD. Mitochodrial  
injury may be the consequence or  the cause of  Parkinson’s  
Disease.  Dysfunct ion leads to  impaired ATP product ion,  which 
in  turn impairs  the ubiqui t in-  proteasomal  system. This  a lso 
contr ibutes  to  oxidat ive and ni t rosat ive s t ress ,  which in  turn 
leads to  a  vicious cycle  of  mitochondrial  injury and oxidat ive 
injury.  Mitochondria  injury is  a lso a  source of  f ree  radicals ,  
impaired calcium homeostasis  and leads to  ini t ia t ion of  cel l -
death via  apoptot ic  pathways.  
Glutaminergic  excess ,  ni t r ic  oxide leading to  ni t rosat ive s t ress  
a lso have been shown to cause mitochondrial  injury.  
Genet ics  is  now emerging  as  a  more common et iological  factor  
of  Parkinson’s  Disease.  Mult iple  genes have been implicated in  
pathogenesis  of  Parkinson’s  Disease and newer ones are  being 
discovered current ly.  
Famil ia l  cases  of  PD have been recognised over  the years .  
However  s ince the inheri tance of  PD could not  be re l iably 
def ined,  the contr ibut ion of  genet ic  factors  was in i t i ta l ly  
discounted.   However  mult iple  famil ia l  ser ies  with autosomal  
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dominant  inheri tance and incomplete  penetrat ion have been 
descr ibed.   
The ear l ies t  gene descr ibed was SNCA, which causes  an 
autosomal  dominant  type of  famil ia l  PD,  with younger  age of  
onset ,  rapid worsening and ear ly  cogni t ive impairment .  This  
gene was ini t ia l ly  label led as  PARK1.   
Alpha-synuclein and ubiqui t in  are  major  components  of  Lewy 
bodies  and mutat ions in  the same can lead to  progression of  the 
disease.  
PARK2 mutat ions are  autosomal  recessive and are  prominent  
causes  of  Young-Onset  Parkinson’s  Disease,  both sporat ic  and 
famil ia l .  They lead to  a  s lowly progress ive d isease wi th 
sustained response to  dopamine and drug induced dyskinesias ,  
dystonia ,  s leep benefi t  and hyperref lexia  may be present .  
PARK3 is  considered to  be a  suscept ibi l i ty  gene s ince i t  leads to  
a  phenotype of  s low disease s imilar  to  sporadic  la te-onset  PD.  
PARK4 mutat ion has  a  var ied cl inical  presentat ion from simple 
postural  t remor to  ful l  blown Parkinson’s  Disease  
PARK5  i s  an autosomal  dominant  mutat ion in  ubiqui t in  -
carboxy-  terminal-  hydrolase L1.  This  plays a  par t  in  ubiqui t in-
proteasomal  degradat ion and defect  of  the gene can affect  
ubiqui t in  c learance leading to  neuronal  damage.  
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PINK1 gene encodes a  mitochondrial  ser ine/ threonine kinase.  
They can resemble the parkin mutat ion.  
PARK7 mutat ions are  a lso cal led DJ-1 mutat ion.  They cause a  
s low onset  disease s imilar  to  parkin  mutat ions.  The DJ-1 
mutat ion leads to  oxidat ive s t ress  in  the basal  gangl ia .  
PARK8 is  the most  common PD gene mutat ion.  I t  affects  protein 
leucine-r ich repeat  kinase 2 (LRRK2).  I t  causes  act ivat ion of  
protein kinase which in  turn leads to  oxidat ive s t ress  and 
damage.  
PARK9  i s  a  gene defect  seen in  Parkinson Plus  Disorders ,  
which is  t ransmit ted in  an autosomal  recessive pat tern.  
Mult iple  named syndromes have been reported to  be associated 
with PD,  namely Gaucher ’s ,  Perry syndrome and Infant i le  
dystonia-Parkinsonism.  
Recent ly  an in-utero mechanism of  dopamine loss  has  been 
postulated in  which in-utero or  per inatal  insul t  leads to  loss  of  
dopaminergic  neurons.  The t ranscr ipt ion factors  for  the var ious 
s tages  of  dopamine product ion have been proposed as  the target  
molecules .  This  cor re la tes  to  the pa thologica l  f ind ing of  
decreased number of  dopaminergic  neurons in  the pat ients  with 
infant i le  parkinsonism. 
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The s taging of  Parkinson’s  Disease is  highly important  for  
p l a n n i n g t h e t r e a t m e n t  p r o g r a m . H o w e v e r  t h e p r i m a r i l y  
importance of  s taging is  for  research purposes .  The s taging can 
be ei ther  c l inical  or  pathological .  
PATHOLOGICAL STAGING 
The pathological  s taging of  Parkinson’s  Disease is  known as  
Braak Staging and was descr ibed by Heiko Braak in  2003.  I t  
was der ived based on post-mortem analysis  of  brain mat ter  of  
pat ients  with diagnosed idiopathic  Parkinson’s  Disease.  He 
descr ibed that  the intracerebral  formation of  Lewy inclusion 
bodies  and Lewy neuri tes  has  a  topographical ly  predictable  
progression.  There are  6  s tages  def ined with 1,2,&3 usual ly  
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Fig.6.  Braak Pathological  staging of  Parkinson’s  disease 
STAGING OF PARKINSON’S DISEASE 
b e i n g p r e s y m p t o m a t i c  P D w h i l e  s t a g e s  3 , 4 , 5 , & 6 a r e  
symptomatic .5  
 The s tages as  descr ibed are  :  
1. Stage 1 (Medulla  Oblongata)  
Lesions are  ini t ia l ly  see in  the dorsal  glossopharyngeal /vagal  
motor  nucleus and int  he anter ior  olfactory nucleus.  This  
explains  why some pre-symptomatic  PD pat ients  have loss  of  
smell .  Lewy bodies  in  the enter ic  nervous system has a lso been 
seen in  this  s tage.  This  explains  why pre-symptomatic  PD 
p a t i e n t s  h a v e g a s t r o i n t e s t i n a l  s y m p t o m s .  T h e o l f a c t o r y 
pathology does not  spread into the surrounding regions whereas  
the les ions in  the brainstem may expand upwards.  
2 .  Stage 2 (Medulla  oblongata  + pont ine tegmentum) 
Here the les ions are  a lso present  in  caudal  raphe nuclei ,  
g igantocel lular  re t icular  nucleus and coeruleus-subcoeruleus 
complex.  
3 .  Stage 3 (Midbrain)  
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The pa thology ex tends to  midbra in ,  par t icu la r ly  the pars  
compacta  of  the Substant ia  Nigra 
4.  Stage 4 (  basal  prosencephalon and mesocortex)  
The les ions extend to  prosencephalon and cort ical  involvement  
confined to  the temporal  mesocortex (  t ransentorhinal  region)  
and al locortex (  CA2- plexus)  with spar ing of  the neocortex.  
5 .  Stage 5 (  Neocortex )  
Neocort ical  involvement  in  the form of  high order  sensory 
associat ion areas  and the prefrontal  neocortex.  
6 .  Stage 6 (  Neocortex )  
Pathology of  the s tage 5 regions along with f i rs t  order  sensory 
associat ion areas  of  the neocortex and premotor  areas ,  with 
occasional  changes in  pr imary sensory and motor  areas .5 
The pathological  s tages  can be predicted using FDOPA- PET 
scanning and is  useful  for  ear ly  diagnosis  of  the disease and 
thus leading to  ear l ier  intervent ion 
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CLINICAL STAGING 
 
 T h e c l i n i c a l  s t a g i n g i s  m u c h m o r e i m p o r t a n t  t h a n t h e 
p a t h o l o g i c a l  s t a g i n g s i n c e i t  i s  m u c h m o r e u s e f u l  i n  
prognost icat ion and predict ing the course of  disease.  
The commonly used s taging system is  the Hoehn and Yahr  
s taging system. The  system was f i rs t  proposed by Melvin Yahr  
and Margaret  Yoehn in  1967 in  the journal  Neurology .  There are  
5  s tages  in  the or iginal ly  proposed s taging and i t  was expanded 
with s tages  1 .5  and 2.5 la ter  in  the modif ied s taging.  
The cl inical  s taging is  based on the symmetr ic i ty  of  the 
symptoms and the severi ty  of  the funct ional  motor  impairment  8 
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Fig.7.  Hoehn And Yahr Staging 7
 The Hoehn and Yahr  scale  is  used as  the reference s tandard for  
tes t ing newly developed scales  of  impairment  in  Parkinson’s  
Disease.  The s tage correlates  s ignif icant ly  with the qual i ty  of  
l i fe  as  measured by other  s tandard scales .  However  i t  i s  re la ted 
inconsis tent ly  to  other  scales  such as  self  care  scales  and the 
Webs t e r  s co re .  The HY sca l e  a l so p red i c t s  t he t ime o f  
progression  of  the disease from one s tage to  the next .  However  
in  recent  t imes the use of  levodopa has  al tered the rate  of  
progression and impaired predict ion of  disease progression.  
Recent ly  FDOPA PET scan of  dopaminergic  act ivi ty  in  the brain 
has  been found to  correlate  wel l  with the Hoehn and Yahr  s tage.  
All  these have led to  Hoehn and Yahr  scale  being the most  
widely used and accepted s taging sys tem for  Parkinson’s  
Disease.  
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Fig.8.  Comparison of  Hoehn and Yahr and Modif ied Hoehn and 
Yahr scale    
There are  a  few l imitat ions of  this  scale  however.  The scale  
does not  different ia te  between impairment  and disabi l i ty, i .e . ,  i t  
does  not  different ia te  between the subject ive and object ive 
components  of  the disease.  And due to  i ts  insis tence on 
la teral i ty  of  the symptoms,  a  severe uni la teral  disabi l i ty  can 
s t i l l  be  under  s taged.  The Hoehn and Yahr  s taging has  only f ive 
s tages  and hence the small  progressions in  disease cannot  be 
made out .  Each s tage is  broadly classif ied and is  not  c lear ly  
def ined by a  se t  c l in ica l /  rad io log ica l  t es t .  I t  i s  h igh ly 
subject ive and s t i l l  does  not  have a  specif ic  s tepwise tes t ing 
program for  c lass i f icat ion.  Hoehn and Yahr  a lso does not  take 
into account  the non-motor  symptoms of  Parkinson’s  Disease.  
However  despi te  these drawbacks,  Hoehn and Yahr  s taging s t i l l  
remains the most  useful  c l inical  s taging system in use.8 
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PAIN IN PARKINSON’S DISEASE 
Pain is  an important  and dis t ress ing symptom of  Parkinson’s  
Disease .  I t  i s  a  wel l  recognised and common non-motor  
symptom. James Parkinson had ini t ia l ly  decr ibed that  “painful  
symptoms can be the f i rs t  s ign of  impairment” .9 The type of  
pain which is  present  is  usual ly  c lassi f ied for  diagnost ic  
purposes  into the fol lowing:  
1. Musculoskeletal  pain 
2. Radicular /  neuropathic  
3. Dystonia-  re la ted 
4. Akathi t ic  discomfort  
5. Central /  pr imary Parkinsonian pain9 
PATHOPHYSIOLOGY OF PAIN IN PARKINSON’S 
DISEASE 
 The exact  pathophysiology of  pain in  Parkinson’s  Disease has  
not  yet  been del ineated.  Mult iple  mechanisms are  descr ibed but  
there  is  no consensus about  which is  the pr imary pathologic  
mechanism. 
Abnormal  somatosensory processing by the basal  gangl ia  has  
been proposed.  This  involves  the substant ia  nigra ,  caudate ,  
putamen,  globus pal l idus,  thalamus and their  connect ions.  I t  has  
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been proposed that  basal  gangl ia  act  as  a  gat ing centre  for  
nocicept ive s t imuli  within the s t r ia tum and l imbic system 
before the nocicept ive s t imuli  are  re layed to  the neocortex for  
percept ion.   
Dopamine has  a lso been shown to ra ise  the pain threshold.  
Absence of  dopamine wil l  lead to  lowering of  the threshold and 
increased and widespread s t imulat ion of  the somatosensory 
cortex in  response to  pain.  
T h e m e d i a l  s p i n o r e t i c u l o t h a l a m i c t r a c t  c o n t a i n s  s l o w 
conduct ing f ibres  that  t ransmit  pain from the pain receptors  to  
the somatosensory cortex.  The t ract  projects  to  the medullary 
core and the mesencephalon.  I t  synapses  in  the parabrachium, 
nucleus g igantocel lu lar i s ,  hypothalamus and per iaqueducta l  
grey matter,  int ra laminar  and medial  thalamic nuclei ,  insula ,  
par ie ta l  operculum, anter ior  c ingulate  cor tex,  amygdala  and 
hippocampus.  This  pathway subserves  the autonomic,  affect ive 
and cogni t ive components  of  pain.  The nucleus parabarachial  
locus ceruleus and the per iaqueductal  grey are  s i tes  of  Lewy 
body deposi t ion in  Parkinson’s  Disease.  This  explains  the 
al tered pain sensat ion and percept ion in  Parkinson’s  Disease. 9  
P a r k i n s o n ’s  D i s e a s e p a t i e n t s  h a v e a l s o d e m o n s t r a t e d a  
diminished pain or  nocicept ive pain ref lex (NFR) threshold as  
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w e l l  a s  a b n o r m a l i t i e s  i n  e v o k e d b r a i n p o t e n t i a l s  a n d 
sympathet ic  skin response (  SSR) on electrophysiologic  tes t ing.
1 0 A d d i t i o n a l l y,  n e w e v i d e n c e h a s  e m e rg e d t h a t  c e n t r a l  
vegetat ive centres  a lso play a  role  in  nocicept ive dis turbances.
10 There are  inconsis tencies  in  the s tudies  reported about  
differences in  the pathway of  pain.  Some studies  have reported 
electrophysiological  nocicept ive dis turbances only in  pat ients  
with Parkinson’s  Disease who experience central  pain.  Other  
s tud ies  r evea led tha t  t he e l ec t rophys io log ica l  noc icep t ive 
abnormali t ies  did not  respond to  dopaminergic  drugs.  This  
a rgues aga ins t  dopamine de f i c i ency be ing the under ly ing 
pathology of  pain in  Parkinson’s  Disease.  10  
The ambiguous nature  of  these s tudies  can be explained by the 
fact  that  most  of  the s tudies  have been based only on a  s ingle  
level  of  pain tes t ing and does not  tes t  across  mult iple  levels  of  
the Central  Nervous System, i .e . ,  spinal ,  subcort ical-vegetat ive,  
cor t ical  ,  subject ive.  The psychophysiological  parameter  of  the 
nocicept ive system which are  usual ly  tes ted are  the Nocicept ive 
Flexion Reflex,  which tes ts  the spinal  level ,  pain-evoked brain 
potent ia ls ,  which tes t  the cort ical  level ,  and subject ive rat ing 
scales ,  which tes t  only the subject ive component  of  the pain.  
Mult iple-method s tudies  are  needed to  descr ibe the conribut ion 
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of  each component  of  the pain pathway to  the nocicept ive 
abnormali t ies  detected in  Parkinson’s  Disease.  This  a lso helps  
to  different ia te  the abnormali t ies  in  the afferent  and efferent  
pathways of  the nocicept ive system.10 
Addi t ional ly  a  “ three- loop” pathway has  been proposed for  the 
p r o c e s s i n g o f  p a i n a n d o t h e r  n o n - m o t o r  s y m p t o m s i n  
Parkinson’s  Disease.  Rodent  models  have shown that  D1- 
mediated pathways between insular  cor tex and basal  gangl ia ,  
are  crucial  in  mediat ing the descending inhibi t ion of  pain.  The 
ant inocicept ive act ivi ty  has  been shown to be dependent  on D2 
receptors  within the s t r ia tum and r ight  medial  temporal  cor tex 
in  heal thy individuals . 11 This  plays  a  role  in  the al tered pain 
percept ion in  pat ients  suffer ing from Parkinson’s  Disease.  
One s tudy combined two method tes t ing ,using Laser-evoked 
brain potent ia ls  (LEP) and sympathet ic  skin responses  (SSR),  to  
evaluate  two different  s i tes  of  pain percept ion.  This  s tudy had 
different  responses  during the On and Off  durat ions of  the 
Parkinson’s  Disease during t reatment .  In  the Off  per iod,  there  
were increased Laser-evoked bra in potent ia ls  and lack of  
habi tuat ion to  Sympathet ic  Skin responses .  This  was reversed in  
the On period.  This  led the authors  of  the s tudy to  propose that  
a ff e ren t  s ens i t i s a t ion o f  the pa in pa thways l eads to  the 
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i n c r e a s e d L a s e r - e v o k e d b r a i n p o t e n t i a l s  a n d a b n o r m a l  
vegetat ive nocicept ive processing in  the brainstem regions can 
dampen the habi tuat ion of  Sympathet ic  Skin Responses .10 This  
has  led to  a  postulat ion that  abnomrnal  over-act ivi ty  of  the 
autonomic nervous system occurs  in  response to  nocicept ive 
s t imuli  in  pat ients  with Parkinson’s  Disease who suffer  central  
pain.   
D o p a m i n e d e f i c i e n c y h a s  d e m o n s t r a t e d a n a m p l i f i c a t i o n 
intrastr ia ta l ly  of  sensory inputs  f rom cort icostr ia ta l  project ions.  
This  leads to  an amplif icat ion of  perceived painful  sensat ions 
leading to  hyperalgesia .  This  mechanism is  especial ly  important  
in  central  Parkinsonian pain but  may extend to  other  types of  
pain perceived in  Parkinson’s  Disease.  11  
Laser  evoked Brain Potent ia ls  have shown reduced N2/P2 
potent ia ls  bi la teral ly,  compared to  controls ,  in  pat ients  with 
Park inson’s  Disease ,  even i f  on ly hemipark inson .  I t  was 
affected only on s ide of  symptoms in  pat ients  not  s tar ted on 
t reatment .  The adminis t rat ion of  levodopa was not  found to  
al ter  these ampli tudes.  The heat-pain threshold was found to  be 
lower in  pat ients  with Parkinson’s  disease when compared to  
controls .  The decrease was more on the s ide of  the body with 
severe  symptoms.  Even within this  group,  the threshold was 
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much lower for  pat ients  suffer ing from pain when compared to  
those who were not .  There was a  difference in  the N2/P2 
ampli tude in  different  types of  pain with muscular  pain having 
a  decreased ampl i tude and the cen t ra l  Park inson ian pa in 
showing an increased ampli tude.  These differences  can be due 
to  differences in  the pathophysiology of  the different  types of  
pain.  However  differences in  methodology used,  such as  the 
t e c h n i q u e ,  n u m b e r o f  a v e r a g e d s t i m u l i  a n d d u r a t i o n o f  
inters t imulus interval  are  a l l  considerat ions that  must  be taken 
into account  before  val idat ing such f indings.   The greater  
r e d u c t i o n i n  N 2 / P 2 a m p l i t u d e i n  p a t i e n t s  w i t h p a i n i n  
Parkinson’s  Disease need not  a lways be an addi t ional  change in  
the pain processing pathways in  this  populat ion,  but  can be the 
resul t  of  something cal led the “segmental  inhibi tory effect” .  
A s tudy by J .A.  Pr iebe et  a l  10 combined three levels  of  pain 
processing in  tes t ing for  abnormali t ies .  The s tudy used a  mult i -
method approach to  tes t  spinal ,  subcort ical-  vegetat ive and 
cort ical  levels .  The s tudy revealed s tarkly contrast ing resul ts  on 
spinal  and vegetat ive levels .  The heat  pain threshold was 
decreased in  the Off  per iod,  but  not  in  the On per iod.  This  led 
to  the conclusion that  dopaminergic  drugs can raise  the heat-
pa in t h r e sho ld .  Howeve r  abno rma l i t i e s  o f  t he vege t a t i ve 
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parameters  is  seen in  both per iods.  The spinal  and cort ical  
parameters  showed only minor  dysfunct ions compared to  the 
vegetat ive parameters .  This  s tudy also showed no s ignif icant  
co r re l a t ion be tween the expe r imen ta l  pa rame te r s  and the 
disease durat ion or  motor  symptom severi ty  as  measured by 
United Kingdom Parkinson’s  Disease Rat ing Scale .10  
This  s tudy also revealed absence of  abnormal i t ies  in  the 
per ipheral  A- del ta  f ibres  and spinothalamic t ract ,  the  central  
a s c e n d i n g n o c i c e p t i v e p a t h w a y s ,  i n  P a r k i n s o n ’s  D i s e a s e 
pat ients .  This  was in  contrast  to  previous s tudies  which showed 
abnormali t ies  of  cor t ical  pain processing.  The abnormali t ies  in  
cort ical  pain processing was,  however,  found to  correlate  wel l  
with  the advances of  motor  symptoms and s tage of  the disease.
10 
The s tudy also revealed that  the relat ionship between the 
ampli tude of  evoked brain potent ia ls  and pain rat ings of  the 
e l ic i t ing s t imul i  was a l te red in  pa t ients  wi th  Parkinson’s  
Disease.  This  points  to  abnormali t ies  of  the dopaminergic  
cort ical-basal  gangl ia-  thalamic-  cor t ical  loop. 10  
However  i t  has  been shown that  only dopaminergic  pathways 
a r e  a f f e c t e d a n d t h e s u b j e c t i v e p e r c e p t i o n o f  p a i n i n  
Parkinson’s  Disease remain unal tered when they are  modulated 
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by adrenergic ,  serotonergic  and opiodergic  mechanisms in  
exper imenta l  models .  These pathways const i tu te  the usual  
descending inhibi tory nocicept ive controls .11 The modulat ing 
effect  of  noradrenergic  and serotonergic  systems on descending 
pain pathways has  been suggested to  be affected in  pat ients  
with Parkinson’s  Disease in  a  few studies .  This  is  supported by 
the s ignif icant  correlat ion of  pain and depression in  pat ients  
with Parkinson’s  Disease.  The ameliorat ive effect  of  duloxet ine 
on central  pain also supports  this  hypothesis .   
Anomalies  of  glutamate metabol ism,  in  the form of  excessive 
act ivat ion of  group III  metabotropic  receptors ,  has  been shown 
to affect  nocicept ion per ipheral ly  and resul t  in  neuropathic  pain 
in  animal  models .   
O t h e r  n e u r o t r a n s m i t t e r s  s u c h a s  N - m e t h y l - D - a s p a r t a t e ,  
adrenal ine and GABA have been implicated in  the modulat ion 
of  pain pathway in  the basal  gangl ia .  The proposed mechanism 
has been an upregulat ion in  NMDA receptors  adn Alpha-2 
adrenoceptors  which play a  role  in  modulat ion of  the sensory 
pathways in  the basal  gangl ia  with spar ing of  the motor  
pathways.   
Funct ional  s tudies  a lso have provided evidence to  confirm the 
abnormal  central  processing of  pain.  PET scans during the Off-  
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phase showed increased pain- induced cort ical  act ivat ion,  in  the 
form of  increased regional  cerebral  blood f low,  which was 
reversed in  the On-phase.  However  this  has  not  correlated 
s ignif icant ly  with increase in  pain threshold in  pat ients  on 
adminis t rat ion of  levodopa and other  dopaminergic  agents . 15 
The areas  which showed act ivat ion were the insula/SII ,  which is  
involved in  discr iminat ive pain processing and the anter ior  
c ingulate  cor tex and the prefrontal  cor tex,  which funct ion as  
affect ive processing areas  of  pain. 17 Pat ients  with pain also had 
lower pain act ivat ion in  r ight  prefrontal  cor tex and poster ior  
insula  while  higher  pain act ivat ion was seen in  the r ight  
anter ior  c ingulate  cor tex.  Levodopa was shown to reduce the 
response to  pain s t imulus in  the poster ior  insula  and anter ior  
c ingulate  cor texin pat ients  with Parkinson’s  Disease without  
pain.  This  effect  could not  be repl icated by apomorphine.17 This  
has  led to  the possibi l i ty  that  levodopa may induce i ts  ant i -
nocicept ive effects  through a  mechanism other  than the increase 
of  dopamine in  the central  nervous system. 
The effect  of  levodopa on the pain thresholds  is  not  yet  
comprehensively elucidated.  A r ise  in  the cold-pain threshold is  
seen ,  but  the degree of  r ise  depends on the underlying disease 
process .  Pat ients  with dyskinesis  and f luctuat ions tend to  have 
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a much greater  r ise  in  threshold compared to  non-f luctuators . 17 
Most  of  the s tudies  including pain response to  levodopa were 
done on subject  populat ions with longer  durat ion of  disease,  
and hence would include pat ients  with t reatment  associated 
complicat ions such as  f luctuat ions and dyskinesias .  This  factor  
has  not  been mentioned in  some of  the s tudies  showing a  
pos i t ive response to  l evodopa ,  bu t  shou ld be t aken in to 
considerat ion when analysing the resul ts .  
Some neurosurgical  s tudies  af ter  Deep Brain St imulat ion have 
also supported the role  of  basal  gangl ia  in  modulat ion of  pain.  
Pal l idotomy or  Globus Pal l idus s t imulat ion by Deep Brain 
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Fig.9.  Factors and mechanisms of  Pain in Parkinson’s  Disease 17
Stimulat ion (ei ther  uni la teral  or  bi la teral) ,  has  demonstrated a  
subject ive improvement  in  Parkinson’s  Disease re la ted pain.15  
 Animal  s tudies  have also supported the role  of  basal  gangl ia  in  
pain processing.  Caudate ,  putamen and globus pal l idus have 
s h o w d i s t i n c t  r e s p o n s e s  t o  t h e r m a l  s t i m u l a t i o n i n  r a t s .  
Lesioning and microinject ion of  somatostat in  in  the caudate  and 
putamen in  animal  models  has  shown an anaesthet ic  effect . 15  
One s tudy showed no differences  in  descending nocicept ive 
inh ib i to ry con t ro l  sys t em ac t iva t ion among pa t i en t s  wi th 
Parkinson’s  Disease with pain,  with   variable  types and 
qual i t ies  of  pain when compared to  those without  pain.  This  
argues against  the involvement  of  this  system in Parkinson’s  
Disease.17 
A review of  s tudies  on the pathophysiology of  pain reported 
that  only mild changes in  pain-processing mechanisms are  seen 
and this  contr ibutes  to  the intermit tent  type of  pain seen in  
pat ients  with Parkinson’s  Disease.  The s tudies  have returned a  
lack of  correlat ion between the degree of  lowering of  pain 
threshold and the severi ty  and intensi ty  of  the pain experienced 
by the pat ient .  However  this  does not  ref lect  a  mutual  exclusion 
between abnormali t ies  of  pain processing pathways and the 
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spontaneous pain experienced in  pat ients  suffer ing from pain in  
Parkinson’s  Disease.17 
All  these f indings point  towards increased act ivi ty  in  both the 
ascending la teral  and medial  pain pathways.  The abnormali t ies  
in  pain processing have also been found in  pat ients  with 
Parkinson’s  Disease which points  to  an underlying process  that  
predisposes  pat ients  to  spontaneous pain but  addi t ional  factors  
are  necessary for  the pain to  manifest .  These factors  have been 
proposed to  be the possible  r isk factors  associated with higher  
prevalence of  pain.  These include female gender,  severe  motor  
complicat ions and other  coexis t ing painful  medical  condi t ions.  
The associat ion of  a  s ingle  genet ic  var iant  with mult iple  pain 
types has  a lso led to  the bel ief  that  the background abnormal  
nocicept ive processing changes are  the same in  a l l  pat ients  with 
pain in  Parkinson’s  Disease,  regardless  of  the type of  pain 
experienced.17 Except  for  central  pain,  a l l  the other  types  of  
pain ,ay develop on this  background abnormali t ies  based on the 
coexis t ing medical  condi t ions and motor  complicat ions.  
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P R E VA L E N C E O F PA I N I N PA R K I N S O N ’ S 
DISEASE  
Var ious s tudies  have reported varying prevalence of  pain in  
Parkinson’s  Disease.  This  had revealed a  wide range from 40% 
up to  83%.11 Almost  40% of  pat ients  with Parkinson’s  Disease 
complain of  painful  symptoms in  one s tudy. 9 Pain has  a lso been 
considered a  premotor  symptom of  the disease.  One s tudy 
reported pain in  upto 25% of  pat ients  before  t reatment  and upto 
40% of  a l l  Parkinson’s  Disease pat ients  in  the ear ly  s tages  of  
disease.  
A Bri t ish s tudy revealed PD-related pain to  be responsive to  
dopaminergic  drugs,  prominent  on the s ide of  motor  symptoms.  
Most  pat ients  suffered from two concomitant  pain syndromes in  
85%, whereas  pain indirect ly  re la ted to  Parkinson’s  Disease was 
1% and pain related to  Parkinson’s  t reatment  was 8%. The non-
Parkinson’s  Disease re la ted pain was found to  be constant ly  
more severe. 12 The number of  pains  was not  found to  increase 
with the s tage of  the disease.  The severi ty  of  pain was found to  
correlate  to  the presence of  depression and other  non-motor  
symptoms.  The “bl ind spot”  in  this  s tudy was the fact  that  
Parkinson’s  Disease pat ients  with severely impaired cogni t ive 
func t ion cou ld no t  be adequa te ly a s sessed rega rd ing the 
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presence,  severi ty  or  type of  pain.  The pain was most  f requent ly 
found to  be intermit tent  and per iodic .  The most  common 
locat ion of  pain was the proximal  extremit ies ,  with most  
pat ients  complaining of  a  cramping,  aching or  feel ing of  
t ightness  in  the proximal  l imbs.  Only a  small  f ract ion of  the 
s tudy popula t ion (4 .9%) were found to  have Park inson’s  
Disease re la ted neuropathic  pain.  This  was in  contrast  to  other  
preceding s tudies  such as  Snider  e t  a l .  who reported higher  
f r ac t i on o f  neu ropa th i c  pa in (11%) .  Howeve r  t h i s  s t udy 
included not  just  pat ients  with Parkinson’s  Disease,  but  a lso 
pat ients  with post-encephal i t ic  Parkinsonism,  who were more 
l ikely to  have sensory abnormali t ies .  This  can account  for  the 
increased prevalence of  neuropathic  pain in  this  s tudy.12 The 
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Fig.10.  Prevalence of  Pain in Parkinson’s  Disease 15
Brit ish s tudy has  another  drawback in  that  i t  d id  not  have a  
control  group to  compare resul ts  with.  A background prevalence 
of  pain in  the elder ly  populat ion has  been est imated at  70 %12 .  
However  in  this  s tudy the prevalence of  pain in  Parkinson’s  
D i s e a s e w a s f o u n d t o  b e h i g h e r  a t  8 5 % . A m o d e l  o f  
“background” non-  Parkinson’s  Disease related pain with a  
“superimposed” pain of  Parkinson’s  Disease was proposed. 12 An 
age-matched control led t r ia l  would be needed to  prove this  
model .  The pain was also reported to  be a  dominant  factor  in  
the qual i ty  of  l i fe  of  a lmost  50% of  these pat ients .  
Another  s tudy in  French out-pat ients ,  showed that  chronic  pain 
was found in  60% of  pat ients ,  of  which 60% was rela ted to  the 
disease and 40% was unrelated.13  
A Norwegian s tudy revealed Parkinson’s  Disease related pain in  
83%, musculoskeletal  pain in  70%, dystonic  pain in  40%, 
radicular  pain in  20% and central  pain in  10%.14  
Chronic  pain has  a lso led to  development  or  aggravat ion of  
depressive symptoms,  more commonly in  e lder ly  individuals .  In  
a  Norwegian s tudy,  67% had pain and this  incidence correlated 
with higher  sever i ty  of  depression.  This  a lso closely correlated 
with higher  degree of  motor  impairment  and more cogni t ive 
impairment  and longer  durat ion of  the disease.  However  this  
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s tudy could not  prove a  direct  causal i ty  between depression and 
pain in  pat ients  with Parkinson’s  Disease.  14  
Pain in  Parkinson’s  Disease is  associated with a  poorer  qual i ty  
of  l i fe .  Pain is  ranked high among the disabl ing symptoms in  
Parkinson’s  Disease in  a l l  s tages  of  the disease.  In  the ear ly  
s tages ,  i t  ranks as  the most  disabl ing non-motor  symptom only 
secondary to  the cardinal  motor  symptoms of  s lowing,  t remor 
and s t i ffness .  In  la ter  s tages  of  the disease i t  ranked s ixth on 
the l is t  of  most  disabl ing symptoms.  Despi te  these f indings,  i t  
s t i l l  remains  unrecognised or  undeclared in  a lmost  40% of  
pat ients  with Parkinson’s  Disease.  15 
Some pat ients  with Parkinson’s  Disease complain of  mult iple  
types of  pain.  In  one s tudy,  two different  types of  pain were 
seen in  24% and three types were reported in  5%. The most  
common si te  of  pain reported in  the s tudy was the back at  74%. 
In the s tudy among outpat ients ,  a  substant ia l  proport ion (46%) 
a t t r ibu ted the i r  pa in d i rec t ly  d i rec t ly  to  the presence of  
Parkinson’s  Disease.15 However,  s ince this  is  highly subject ive 
and the cause of  pain cannot  be easi ly  different ia ted,  fur ther  
l a r g e - s c a l e ,  c o n t r o l l e d s t u d i e s  a r e  n e e d e d t o  e l i m i n a t e  
subject ive bias .  
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The presence of  pain was reported in  some studies  to  be 
s ignif icant ly  associated with female gender,  younger  age of  
onset  of  disease ,  d isease severi ty  and depression.  However  
these f indings have been inconsis tent  and negat ive correlat ions 
have been demonstrated in  other  s tudies .15 The cause for  this  
discrepancy could be the small  sample s ize ,  non-representat ive 
s tudy populat ion or  self  ra t ing data  col lect ion which remains 
highly subject ive.15  
One other  factor  proposed to  be associated with Parkinson’s  
Disease re la ted pain is  pre-exis t ing medical  condi t ions such as  
d i a b e t e s  m e l l i t u s ,  o s t e r o p o r o s i s ,  r h e u m a t i c  d i s e a s e ,  
degenerat ive joint  and disc  disease and ar thr i t is .  A genet ic  
component  of  the predisposi t ion to  pain has  a lso been recent ly  
proposed.  The genes in  quest ion are  var iants  in  SCN9A and 
FAAH genes. 17 
A systematic  review of  prevalence s tudy by Broen et  a l .  us ing 
modif ied QUADAS tool  shed more l ight  onto the character is t ics  
of  pain.  This  review reported that  the prevalence var ied across  
8  s tudies  f rom 40% to 85% with a  weighted average of  67.6%. 
This  wide var iabi l i ty  was could be explained by methodological  
dispar i t ies ,  diff icul t ies  in  c lear  cut  def ini t ion of  chronic  pain 
and inabi l i ty  to  dis t inguish Parkinson’s  Disease related and 
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unrelated pain and a  select ion bias  due to  most  of  these s tudies  
being in  ter t iary care  centres .  Parkinson’s  Disease related pain 
was reported in  3  s tudies  with a  prevalence of  57.6%. Pain in  
the lower l imbs was reported as  the most  f requent  a t  47.2%. 
Back pain was seen in  14.3% ,  pain in  the upper  l imbs was 
13.8% and neck and shoulder  pain was seen in  12.4%.16 The 
pain in  the lower l imbs is  more l ikely to  be neuropathic  Among 
the types of  pain from the s tudies ,  musculoskeletal  pain was the 
most  common in 46.4% of  a l l  Parkinson’s  Disease pat ients  and 
55.6% of  pat ients  with Parkinson’s  Disease related pain.  Next  
in  prevalence was dystonic  pain in  19.6%, radicular  pain in  
9 . 1 % a n d c e n t r a l  p a i n i n  5 . 6 % . A k a t h i s i a  w a s r e p o r t e d 
inconsis tent ly  and could not  be def ini t ively descr ibed.  I t  was 
assumed that  this  only consis ted of  a  minori ty  of  pat ients  with 
pa in i n  Pa rk in son ’s  D i sea se . 16 Pa in f r equency i s  u sua l l y  
proport ional  to  severi ty  of  motor  s igns and symptoms.  However  
pain can manifest  independent  of  motor  problems in  25-64% of  
pat ients  with Parkinson’s  Disease.17 
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SYMPATHETIC SKIN RESPONSE (SSR)  
The sympathet ic  skin response is  a  response to  pain mediated 
via  the medial  pain system.The impulse is  carr ied by A-del ta  
f ibres  to  the spinothalamic t ract  and carr ied upward to  the 
medial  thalamic nuclei .  From this  ,  afferents  are  given to  the 
anter ior  c ingulate  cor tex and the higher  cor t ical  centres  such as  
the insula  and the somatosensory cortex.  An efferent  f rom the 
anter ior  c ingulate  cor tex projects  to  the anter ior  hypothalamus,  
which in  turn produces the Sympathet ic  Skin Response via  
fur ther  re lays  in  the brainstem, vegetat ive centres  and post-
gangl ionic  C-  f ibres .  In  pat ients  with Parkinson’s  Disease,  the 
efferent  pathways in  this  ref lex are  affected s ince they contain 
t h e v e g e t a t i v e n u c l e i .  T h e s e n u c l e i ,  e s p e c i a l l y  t h e 
p e r i a q u e d u c t a l  g r a y m a t t e r  ( PA G ) ,  c o n t a i n d o p a m i n e rg i c  
neurons which can be affected in  Parkinson’s  Disease.  One 
more fact  to  be taken into account  a t  this  juncture  is  that  the 
pathology of  Parkinson’s  Disease s tar ts  in  the brainstem and 
ascends upwards.  Hence the per iaqueductal  gray matter  is  
affected ear ly  in  the course of  the disease,  as  determined by 
Braak s taging.  This  accounts  for  the minimal  pain abnormali t ies  
detected in  the s tudy by J .A.  Pr iebe et  a l  in  pat ients  with ear ly  
s tages  of  Parkinson’s  Disease.10 The Lamina I  of  the dorsal  horn 
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of  the spinal  cord has  shown aggregat ion of  Lewy Bodies  in  
Parkinson’s  Disease .  This  can contr ibute  to  the increased 
temporal  summation of  sensory s t imuli  and decreasing the 
nocicept ive s t imulus threshold at  the spinal  level .  11 However  
this  has  not  correlated with the intensi ty,  qual i ty  or  dis t r ibut ion 
of  muscular  or  neuropathic  pain.  
NOCICEPTIVE FLEXION RESPONSE (NFR) & LASER 
EVOKED BRAIN POTENTIALS (LEP)  
This  is  a  motor  act ion in  response to  a  painful  s t imulus.  The 
Nocicept ive Flexion Response is  a  spinal  level  tes t  of  pain of  
modulat ion and percept ion.  I t  depends on an intact  afferent  
pathway of  A- del ta  f ibres  to  the dorsal  horn and an intact  
efferent  pathway through spinal  c i rcui ts .  These pathways have a  
top-  down control  f rom the thalamus via  brainstem and an 
inhibi tory effect  f rom the substant ia  nigra  to  the thalamus and 
brainstem,i .e . ,  the  medial  pain pathway.   This  is  a l tered in  
Parkinson’s  Disease,  leading to  a  decreased pain threshold to  
Nocicept ive Flexion Response,  a long with increased ampli tudes 
o f  t h e r e s p o n s e .  T h i s  p o i n t s  t o w a r d s a  s p i n a l  s e g m e n t  
d is turbance in  nocicept ion .  This  a l te ra t ion in  Nocicept ive 
Flexion Response threshold has  been showed to  be responsive 
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t o  d o p a m i n e rg i c  d r u g s s u c h a s  l e v o d o p a . 1 0 T h e l a c k o f  
descending inhibi t ion of  pain can also contr ibute  to  referred 
pain and secondary hyperalgesia .  11 The nocicept ive spinal  
response is  the ear l ies t  abnormali ty  of  pain percept ion detected 
in  Parkinson’s  Disease.  I t  may be abnormal  even when the 
subject ive assessment  of  provoke pain remains unal tered.  The 
abnormali ty  of  the nocicept ive f lexion response correlates  with 
the presence of  musculoskeletal  pain due to  abnormal  pain 
processing in  the spinal  cord.  The involvement  of  the medial  
pain pathway can be demonstrated ear ly  by PET scans.  This  
does not  correlate  with the severi ty,  intensi ty,  qual i ty  or  
dis t r ibut ion of  pain.  Both the nocicept ive f lexion response and 
laser-evoked brain potent ia ls  were found to  have lowered 
thresholds  even in  pat ients  with Parkinson’s  Disease who did 
not  have pain.  17 However  using a  lower  number  of  averaged 
s t imuli  and longer  inters t imulus intervals  has  recorded normal  
Laser-evoked brain potent ia ls  in  pat ients  with Parkinson’s  
Disease who do not  suffer  f rom pain.  Hence the methodology 
used is  a lso of  pr ime importance in  tes t ing.17  
L e v o d o p a i n t a k e ,  a c u t e l y ,  h a s  s h o w n i n c r e a s e i n  t h e 
Nocicept ive f lexion response threshold,  even in  pat ients  with 
Parkinson’s  Disease without  pain.  This  was disputed in  a  la ter  
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s tudy.  Levodopa also had no effect  on the N2/P2 ampli tudes.  
The threshold for  Nocicept ive f lexion response was found to  be 
inversely related to  the severi ty  of  motor  s igns.  No such 
relat ionship was found for  N2/P2 anpl i tude lowering.   
ROLE OF PHASE (ON/OFF)  
Most  of  the parameters  have shown insignif icant  differences  in  
the pain tes t ing during  the two phases .  Only the heat-pain 
threshold has  shown the pat tern of  being abnormally low in the 
Off  phase which was reversed in  the On phase.  This  points  
against  an effect ive response of  pain to  dopaminergic  drugs.  
This  lack of  difference in  downregulat ion of  Sympathet ic  Skin 
Reflex has  been explained by three proposed mechanism: 
1. The s t imulat ion of  the basal  gangl ia  by medicat ion is  not  
suff ic ient  to  provide adequate  act ivi ty  of  the Per iaqueductal  
Gray matter,  which is  essent ia l  for  Sympathet ic  Skin Reflex.  
2. The degenerat ion of  the Autonomic Nervous System in the 
form of  chol inergic  post-  gangl ionic  sympathet ic  f ibres  
a t tenuates  this  ref lex.  
3. The vegetat ive level  of  pain percept ion depends on other  
neurotransmit ters ,  the loss  of  which in  Parkinson’s  Disease 
is  not  replaced by dopaminergic  t reatment .  
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The hypersensi t ivi ty  to  pain is  usual ly  higher  in  the Off  per iod 
and is  amenable  to  t reatment  with dopaminergic  agents .  In  some 
pat ients  though,  paradoxical  decrease in  pain percept ion has  
been reported in  the Off  phase.  This  contradict ion can be 
explained by the theory that  Off  per iod also worsens motor  
impairment ,  which resul ts  in  decreased facial  expression of  the 
perceived pain,  which can improve with t reatment .10  
A systemat ic  analysis  of  s tudies  has  shown a s ignif icant  
improvement  of  the pain af ter  dopaminergic  drugs was seen 
only in  28.6%. Broetz  e t  a l .  found no correlat ion between pain 
and the durat ion in  the Off  phase.  This  lack of  associat ion led 
to  the hypothesis  that  other  mechanisms might  a lso underl ie  
pain.16 
CLINICAL PAIN SYNDROMES 
Pain in  a  pat ient  with Parkinson’s  Disease should be considered 
a long wi th o the r  ca rd ina l  symptoms o f  PD.  The pa in fu l  
symptoms may be exacerbated,  re l ieved or  not  a l tered by PD 
treatment .  This  is  an important  his tory that  should be always 
quest ioned in  pat ients  complaining of  pain.   
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Ford ini t ia l ly  c lass i f ied pain in  Parkinson’s  Disease into 5  
types:12 
1. M u s c u l o s k e l e t a l  p a i n d u e t o  P a r k i n s o n i a n r i g i d i t y  o r  
musculoskeletal  abnormali t ies  
2. Radicular-  neuropathic  pain due to  a  root  or  per ipheral  
neurve les ion 
3. Dystonic  pain re la ted to  ant i -Parkinsonian medicat ions 
4. Central  or  pr imary pain related  to  dopaminergic  drug dosing 
and t iming 
5. Akathis ia ,  which can be drug induced or  re la ted to  Off  
per iods 
Another  scheme of  c lass i f icat ion of  pain in  Parkinson’s  Disease 
was proposed by Serratr ice  and Michel  in  1999.12 The pain was 
classif ied into two headings:  
1. Primary pain syndromes-  direct ly  re la ted to  Parkinson’s  
Disease such as  cramps or  paresthesia  
2. S e c o n d a r y p a i n s y n d r o m e s -  p o s t u r a l  d i s o r d e r s  
osteoarthr i t is ,e tc .   
Dys tonic  pa in i s  d iagnosed when the pa in presen ts  wi th 
wri thing,  cramping or  postur ing of  a  body par t .   
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Akathis ia  refers  to  an intensely unpleasant  sensat ion that  need 
not  be painful  but  merely uncomfortable .  
 Pr imary Parkinsonian pain is  suspected to  be a  central  pain 
occurr ing due to  defect ive modulat ion of  the pain pathways.  
This  is  unrelated to  the motor  symptoms and is  diagnosed par t ly  
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 Fig.11.  Classif icat ion of  pain in Parkinson’s  Disease 15  
on the cl inical  presentat ion and par t ly  by exclusion of  other  
causes  of  pain.   
The pain in  PD has been found to  improve with medicat ions for  
Parkinsonism.  This  has  led to  grouping of  var ia t ion of  pain 
along with non-motor  complicat ions.  The f luctuat ion may also 
be due to  f luctuat ion of  the motor  tone in  skeletal  muscles  that  
character is t ical ly  occurs  in  PD. 9  
Myofascial  pain syndrome is  another  common type of  pain seen 
in  a lmost  79% of  pat ients  with pain in  Parkinson’s  Disease.  
This  poses  a  diagnost ic  chal lenge s ince the pain is  usual ly  a  
referred pain due to  a  secondary hyperalgesia  and is  spat ia l ly  
dis tant  f rom affected muscles .11 
The classif icat ion of  pain in  Parkinson’s  Disease according to  
the above mentioned systems is  diff icul t  due to  a  s ignif icant  
amoun t  o f  ove r l ap be tween t he d i f f e r en t  de sc r i bed pa in 
syndromes.  The lack of  c lear  object ive measures  and the 
i ncomple t e  unde r s t and ing o f  t he mechan i sm o f  t he pa in 
syndromes also contr ibutes  to  the confusion.  A newer updated 
classif icat ion was proposed by Ha,  Jankovic  et  a l . ,  which 
included other  pain syndromes such as  per ipheral  neuropathic  
pain and oral  and geni ta l  pain15.   
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MUSCULOSKELETAL PAIN 
Aching ,cramping and joint  pains  have been descr ibed in  PD 
very commonly.  The prevalence of  musculoskeletal  pain in  
Parkinson’s  Disease has  been reported to  be as  high as  70%.15 
This  type of  pain is  probably related to  the increased tone,  
r igidi ty,  abnormal  postur ing and s t i ffness  of  muscles .  The 
cramping is  more common in the neck,  arm and calf  while  the 
joint  aches are  more common in the shoulder,  hips  ,  knees and 
ankles .  This  pain increases  during long per iods of  Parkinsonian 
symptoms.  Hence,  in  theory,  the pain should respond to  ant i -  
Parkinsonian medicat ion,  unless  contractures  have formed.9 The 
pain may be the present ing symptom of  PD.  For  example,  f rozen 
shoulder  has  been reported not  infrequent ly  as  the present ing 
symptom of  Parkinson’s  Disease.  The excessive contractures  
can lead to  a  s tooped posture  known as  camptocormia.  Shoulder  
pain may be the ini t ia l  presentat ion of  Parkinson’s  Disease,  
even be fo re the onse t  o f  moto r  symptoms .Th i s  symptom 
correlated s ignif icant ly  with the s ide of  subsequent  maximal  
motor  severi ty.   A marked l imitat ion of  movements  of  the 
shoulder  joint  with decreased range of  movements  and local ised 
pain,  known as  “frozen shoulder” ,  is  a  common f inding in  
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Parkinson’s  Disease.  The pat ients  with Parkinson’s  Disease 
were found to  have a  21-  t imes higher  chance of  suffer ing from 
frozen shoulder  compared to  age and sex matched controls .  
Supraspinatus  tear,  subcoracoid effusion and acromioclavicular  
joint  changes have been demonstrated on MRI,  which correlated 
wel l  wi th UPDRS scores .  Rheumat ic  a r th r i t i s  i s  a  c lose 
different ia l  diagnosis ,  s ince the f indings of  joint  involvement  
and pain wil l  mimic i t .  The classical  pat tern of  involvement  in  
Parkinson’s  Disease is  f lexion of  the metacarpophalangeal  
joints  and dis ta l  interphalangeal  joints  with extension of  the 
proximal  interphalangeal  joint ,  wi th  ulnar  deviat ion.15 These 
f i n d i n g s a r e  c a l l e d “ s t r i a t a l  h a n d a n d f o o t ”  a n d 
“pseudorheumatoid deformit ies” .  These f indings can be rel iably 
different ia ted from rheumatoid ar thr i t is  by the character is t ic  
a b s e n c e o f  i n f l a m m a t o r y c h a n g e s i n  t h e j o i n t s  a n d t h e 
uni la teral i ty  of  the f indings.15 Pat ients  with muscular  pain were 
also found to  have reduced N2/P2 ampli tudes on s t imulat ion 
with CO2 for  Laser  Evoked brain Potent ia ls .  This  has  led to  the 
suggest ion that  muscular  pain also has  a  central  component .15 
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RADICULAR/ NEURITIC PAIN  
Radicular  pain is  seen in  14% of  pat ients  with PD who complain 
o f  pa in . 9 There migh t  be pa res the t i c  sensa t ions such as  
coolness ,  numbness ,  t ingl ing,  e tc . ,  which might  be mistaken for  
central  pain or  sensory symptoms.  The prevalence in  one s tudy 
was around 20%.15 These must  be always tes ted for  compressive 
r o o t  o r  p e r i p h e r a l  n e r v e i n j u r y w h i c h n e e d s f o c u s e d 
management .  Per ipheral  nerve involvement  can also occur  as  a  
par t  of  the pathological  process  of  Parkinson’s  Disease.  Alpha-
synuclein accumulat ion within the sensory afferents  has  been 
demonstrated.  Levodopa adminis t ra t ion is  bel ieved to  interfere  
with cobalamin metabol ism in the per ipheral  nervous system. 
This  can lead to  e levated methylmalonic  acid 15 .Both these 
mechanisms can contr ibute  to  neuropathic  pain which is  due to  
per ipheral  neuropathy in  pat ients  with Parkinson’s  Disease.11 
The muscular  r igidi ty  of  spinal  muscles  can also leads to  
abnormali t ies  in  the ver tebral  column and interver tebral  discs .  
This  can give r ise  to  radicular  pain,  which typical ly  manifests  
as  low back pain.  11 In  contrast  to  other  types of  pain in  
Parkinson’s  Disease ,  the laser-evoked bra in potent ia ls  are  
decreased in  ampli tude in  pat ients  with radicular  or  per ipheral  
neuropathic  pain.  Abnormal  joint  posi t ion sense has  a lso been 
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r e p o r t e d i n  s o m e p a t i e n t s  w i t h P a r k i n s o n ’s  D i s e a s e . 1 5 
Neurodegenerat ion of  nociceptors  has  been found as  an ear ly  
feature  of  Parkinson’s  Disease.  Skin biopsies  showed reduced 
nerve f ibres  and Meissner 's  corpuscles ,  with a  decrease in  
unmyelinated nerve f ibre  densi ty.15 
DYSTONIC PAIN  
A diagnosis  of  dystonic  pain is  made when pat ient  complains  of  
pain and has  dystonia  in  the form of  abnormal  cramping,  
twist ing or  postur ing of  a  l imb or  other  body par t .  The 
p r e v a l e n c e w a s r e p o r t e d t o  b e a r o u n d 4 0 % . 1 5 T h e p a i n 
character is t ical ly  responds to  dopaminergic  t reatment  and the 
t iming of  the pain is  c lassical ly  ear ly  in  the morning before 
taking drugs or  la te  in  the day,  during the wearing off  effect  of  
the drugs.  The dystonia  can be severe enough to  cause joint  
dis locat ion,  commonly  a t  the shoulder.  
The ear ly  morning pain can be rel ieved by levodopa or  be 
severe  enough to  require  subcutaneous apomorphine inject ions.  
The dystonia  may be rel ived by botul inum toxin inject ions and 
deep brain s t imulat ion of  the Subthalamic Nucleus or  the 
Globus Pal l idus Interna.  However  paradoxical ly,  deep brain 
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s t imulat ion can also cause exacerbat ion of  the pain due to  
s t imulat ion of  the internal  capsule .9  
The dyskinesia  associated pain has  been shown to be the most  
amenab le  to  pa l l i a t ion by dopamine rg ic  d rugs .  The pa in 
threshold was found to  be reduced in  the off  per iod of  pat ients  
with dyskinesias .  The involvement  of  the l imbic cor tex and 
other  associated s t ructures ,  especial ly  the reward system, has  
been pos tu l a t ed .  The ove rac t i v i t y  o f  t he se s t r uc tu r e s  i n  
Parkinson’s  Disease can lead to  abnormal  pain percept ion.  11 
Dopaminergic  project ions f rom the ventral  tegmentum to the 
nucleus accumbens,  which const i tutes  the mesol imbic pain 
inhibi tory pathway,  can be involved in  Parkinson’s  Disease.  
This  again leads to  dis inhibi t ion of  pain pathway act ivat ion and 
leads to  increased nocicept ion.  11 
Dystonia ,  especial ly  involving the feet ,  may be the present ing 
symptom of  Parkinson’s  Disease.  This  is  more commonly seen 
in  Young-onset  Parkinson’s  Disease,  especial ly  when associated 
with the Parkin gene mutat ion.  In  other  pat ients ,  dystonia  more 
commonly occurs  a  complicat ion of  dopaminergic  t reatment .  
This  type of  dystonia  can present  a t  var ious s tages of  the 
medicat ion cycle  including the fol lowing:  
1. Early morning,  off-medicat ion-  seen in  15% 
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2. Diphasic  dystonia  
3. Peak dose dystonia  
AKATHISIA  
Akathis ia  refers  to  an inner  res t lessness  which is  a  common and 
potent ia l ly  disabl ing symptom of  Parkinson’s  Disease.  This  
leads to  an inabi l i ty  to  remain s t i l l ,  wi th a  constant  urge to  
keep moving.  This  was seen in  around 45% of  pat ients  suffer ing 
from Parkinson’s  Disease.15This  needs to  be dis t inguished from 
other  condi t ions such as  dyskinesias ,  anxiety and depression.  
The pr imary pathology is  a  dopamine defect  in  the mesocort ical  
pathway.  
The symptom responds in  about  50% of  pat ients  to  increase in  
dopaminergic  dosing.9 Akathis ia  needs to  be managed properly 
s ince i t  might  be severe  enough to  impair  the act ivi t ies  of  dai ly  
l iving.  
Akathis ia  correlates  with the severi ty  and age of  onset  of  
Parkinson’s  Disease.  I t  has  been misdiagnosed as  Rest less  Leg 
Syndrome,  which is  another  sensory-motor  disorder  which can 
occur  in  Parkinson’s  Disease.  The two condi t ions can be 
different ia ted based on the character is t ics  of  Rest less  Leg 
Syndrome,  which is  “an urge to  move the legs ,  par t icular ly  a t  
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nigh t” ,  a s  opposed to  genera l i sed res t l s sness  as  seen in  
akathis ia . 15 
CENTRAL PAIN  
Central  Parkinsonian pain is  def ined as  pain as  par t  of  the 
disease per  se  ,  and not  due to  dystonia ,  nerve injury or  
musculoskeletal  pain.  I t  was ini t ia l ly  descr ibed by Souques in  
19219.  The prevalence in  one s tudy was reported to  be around 
10%.15 The locat ion of  abnormal  pain syndromes are  head,  neck,  
epigastr ium, abdomen,  geni ta l ia ,  face ,  pharynx,  pelvis  or  
rectum, These are  s i tes  where neuropathy or  dystonia  are  less  
l ikely to  occur.  The pain may have different  character is t ics  but  
usual ly  are  dis t ress ing,  re lent less  and obsessional  that  may 
overshadow other  symptoms of  Parkinsonism.  The pain may 
respond sometimes to  dopaminergic  t reatment .  I f  i t  does  ,  the  
character  of  the pain is  usual ly  visceral  or  autonomic in  or igin.  
I t  f luctuates  according to  the drug levels  in  the serum. In those 
w h o t h e p a i n d o e s n o t  r e s p o n d t o  d o p a m i n e rg i c  d r u g s ,  
convent ional  ant i  pain medicat ions may be t r ied.  However  the 
effec t iveness  of  the drugs i s  not  def in i te .  The pa in can 
character is t ical ly  be descr ibed as  “poorly local ised,  constant ,  
bo r ing ,  ine ffab le ,  no t  l imi t ed to  a  de rmatome o r  neura l  
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dist r ibut ion”.15 This  central  pain syndrome can also be seen in  
other  diseases  of  the central  nervous system such as  s t roke,  
myelopathies  and mult iple  sclerosis .  Central  pain was found in  
one s tudy to  correlate  with Off-per iod non-motor  symptoms,  
wi th the a t tendant  f luc tuat ions wi th t rea tment .15 Ora l  and 
geni ta l  burning pain can occur  in  pat ients  with Parkinson’s  
Disease.  This  is  usual ly  considered a  tardive syndrome of  the 
disease.15 
PAIN SCALE 
There a re  mul t ip le  sca les  ava i lab le  for  quant i fy ing pa in .  
However  a lmost  a l l  of  them are  subject ive with the object ive 
scales  s t i l l  in  development .   
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Fig12.Visual  Analog Pain Scale  
Visual  Analog Scale  is  a  psychometr ic  response scale  which is  
re la t ively easy to  adminis ter.  The pat ient  is  asked to  scale  their  
level  of  agreement   
with the adminis tered quest ion along a  cont inuum from least  
agreement  to  most  agreement .  This  helps  to  quant i fy  a  highly 
subject ive var iable  such as  pain into more discrete  values .  
There are  other  scales  to  assess  pain in  Parkinson’s  Disease 
such as:  
1. UPDRS Part-  I I ,  i tem 17 (  sensory symptoms) 
2. Brief  Pain Inventory 
3. McGil l  Pain Quest ionnaire  (MPQ) 
4. Douleur  Neuropathique (DN-4)  
5. PainDETECT 
6. Neuropathic  Pain Symptoms Inventory 
The visual  analog scale  remains the most  commonly used scale  
to  quant i fy  pain in  Parkinson’s  Disease due to  i ts  ease of  
adminis t rat ion.11 The Visual  Analog Scale  is  useful  but  cannot  
wel l  character ise  intermit tent  pain,  as  seen in  pat ients  with the 
On-Off  f luctuat ions of  pain.
The UPDRS scale  does not  provide information on the type of  
pain and hence does not  help in  the classi f icat ion of  pain and 
decis ion on t reatment . 11 
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The short  form of  the Brief  Pain Inventory has  been found to  be 
effect ive in  quant i fying the intensi ty  of  pain and i ts  impact  on 
act ivi t ies  of  dai ly  l iving.  This  has  found use in  pat ients  with 
Parkinson’s  Disease.  
T h e M c G i l l  P a i n Q u e s t i o n n a i r e  h e l p s  i n  d i f f e r n t i a l l y  
quant i fying the different  aspects  of  pain such as  sensory-
discr iminat ive,  affect ive and evaluat ive.  This  different ia t ion 
has  been useful  in  point ing out  difference in  pain response to  
var ious t reatment  modal i t ies .  
Douleur  Neuropathique measures  only neuropathic  pain,  a long 
with PainDETECT and Neuropathic  Pain Systems Inventory.  I t  
i s  not  sensi t ive for  the other  types of  pain.  However  the 
D o u l e u r  N e u r o p a t h i q u e h a s  a  v e r y h i g h s e n s i t i v i t y  a n d 
specif ic i ty  for  the diagnosis  and quant i f icat ion of  neuropathic  
pain.  
The Neuropathic  Pain Systems Inventory is  helpful  in  the 
fol low up of  the neuropathic  pain and also helps  to  character ise  
t h e p a i n a c c o r d i n g t o  t h e c l u s t e r i n g o f  s y m p t o m s i n t o 
spontaneous,  evoked or  paroxysmal  pain.11  
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The importance of  the different  aspects  of  pain was shown in a  
s tudy,  which tes ted response of  pain to  SubThalamic Nucleus- 
D e e p B r a i n S t i m u l a t i o n ( S T N - D B S ) .  T h i s  s h o w e d a n 
improvement  in  the sensory and affect ive aspects  of  pain,  and 
not  the evaluat ive,  post  surgery.  This  s tudy also showed a  more 
robust  improvement  in  musculoskeletal  pain when compared to  
neuropathic  pain,  in  pat ients  with Parkinson’s  Disease.11 
The assessment  of  pain in  Parkinson’s  Disease needs  to  take 
into account  mult iple  var iables  so as  to  avoid bias .  The motor  
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Fig.13.  Taxonomy of  Pain according to Marburg-Sao-Paulo-Cretei l  
Quest ionnaire for Pain in Parkinson’s  Disease 11 
s ta tus  of  the pat ient ,  the  t reatment  given (  medical  or  surgical)  
and i ts  complicat ions (off  s tage /  dyskinesias)  must  a l l  be 
noted.   
The t iming of  pain and i ts  associat ion with the motor  and non-
motor  s ta tus  of  the pat ient  helps  to  l ink the pain to  Parkinson’s  
Disease.  Given the high prevalence of  chronic  pain syndromes 
in  older  age groups,  in  whom Parkinson’s  Disease is  most  
prevalent ,  these factors  help in  es tabl ishing a  connect ion 
between the pain and Parkinson’s  Disease.  
There are  a  couple  of  quest ionnaires  in  development  for  the 
s tudy of  pain in  Parkinson’s  Disease.  One is  being developed by 
the non-motor  s tudy group of  the Internat ional  Parkinson and 
Movement  Disorder  Society.  Another  is  the “Marburg-  Sao 
Paulo-  Cretei l  Quest ionnaire  for  Pain in  Parkinson’s  Disease”.11 
This  takes  into account  three important  var iables:  
1. Temporal  associa t ion of  onset  of  pain and Parkinson’s  
Disease symptoms,  excluding other  causes  
2. Dependence of  pain on motor  f luctuat ions 
3. Dependence of  pain on ant i -Parkinsonian t reatment  
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COGNITION AND PAIN 
Cognit ive funct ions in  the general  populat ion have been found 
to  be inversely related to  pain.  Execut ive funct ioning and 
at tent ion are  the domains more commonly s tudied to  correlate  
with pain.  Processing of  pain shows s ignif icant  overlap with an 
at tent ion-specif ic  network,  affect ing at tent ion.  The degree of  
affect ion correlates  with the severi ty  of  the pain.  A higher  
MMSE (Mini  Mental  State  Examinat ion)  was shown to correlate  
with  a  bet ter  pain tolerance and higher  thresholds .  This  can be 
explained by the abi l i ty  to  central ly  integrate  the mult iple  
facets  of  pain.   
In  pat ients  with Parkinson’s  Disease,  neocort ical  regions are  
involved la te  in  the s tage of  disease and this  can be associated 
with decrease in  pain.  However  the fact  that  pat ients  with 
severe  cogni t ive impairment  have diff icul ty  in  expressing and 
communicat ing their  pain,  this  confounding factor  must  be 
taken into account .   
Both impaired cogni t ion and pain are  non-motor  symptoms of  
Park inson’s  Disease .  Hence the in te rac t ion be tween them 
becomes s ignif icant  in  planning the t reatment  s t ra tegy of  the 
pat ients .  
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In  a  s tudy by Engels  e t  a l . ,  the  f indings were contrary to  the 
hypothesis  proposesd above.  Cogni t ive funct ion showed no 
c o r r e l a t i o n w i t h p a i n .  H o w e v e r  m o o d d i s o r d e r s  s t r o n g l y 
inf luenced the pain response and the presence and severi ty  of  
spontaneous pain in  pat ients  with Parkinson’s  Disease.   
This  absence of  correlat ion might  be at t r ibuted to  the fact  that  
n e u r a l  f u n c t i o n a l  r e o rg a n i s a t i o n o c c u r s  i n  p a t i e n t s  w i t h 
c o g n i t i v e i m p a i r m e n t ,  s u c h t h a t  t h e a r e a s  o f  c o g n i t i v e 
execut ive processing in  these  pat ients  is  different  f rom those 
in  normal  individuals .  The al terat ion of  execut ive funct ion 
leads to  lack of  overlap with pain processing areas  .  This  
pheonomenon is  a lso seen in  Mult iple  Sclerosis .  Funct ional  
s tudies  in  Parkinson’s  Disease have concluded that  there  is  
hyperconnect ivi ty  ear ly  in  the disease and hypoconnect ivi ty  as  
the disease progresses  with cogni t ive impairment ,  Chronic  pain 
also can cause loss  of  gray matter  f rom pain areas  such as  
a n t e r i o r  c i n g u l a t e  c o r t e x a n d i n s u l a .  T h i s  m a y b e a  
compensatory mechanism. Both these f indings can explain the 
lack of  cor re la t ion of  pa in and cogni t ion in  Park inson’s  
Disease .  In  cont ras t ,  anxie ty and depress ion were h ighly 
predict ive of  pain.  This  correlat ion could be bidirect ional  and 
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can lead to  a  cont inuous feedback mechanism of  pain and mood 
disorders .  18 
TREATMENT OF PAIN  
The adequate  management  of  pain should s tar t  with an accurate  
c lassif icat ion of  the type and character is t ics  of  the pat ient .  
Based on these,  a  few basic  pr inciples  of  t reatment  have been 
proposed.  Pain associated with Off  phase and f luctuat ions of  
the motor  symptoms should be t reated to  e l iminate  these 
f luctuat ions.11 This  should consis t  of :  
1. Long-last ing levodopa formulat ions for  ear ly  morning and 
nocturnal  akinesis .  
2.  Catecholamine-  O- methyl  t ransferase inhibi tors ,  a long with 
shortening of  dose intervals  of  levodopa for  end-of-dose 
akinesis .  
3. Dystonic  pain,  more commonly seen in  the Off  per iod,  and of  
high severi ty,  are  to  be managed with long-act ing levodopa 
in  the evenings and fast-act ing formulat ions in  the ear ly  
morning.  
4. Rotigot ine t ransdermal  patches used once a  day also has  a  
protect ive effect  on f luctuat ions and improves s leep qual i ty.  
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Subthalamic Nucleus-  Deep Brain St imulat ion has  been shown 
to have an effect  on pain,  independent  of  i ts  effect  on motor  
symptoms.11 I t  has  been found to  rel ieve pain in  40%-80% of  
Parkinson’s  Disease pat ients  post-surgical ly.  The correlat ion of  
effect  on pain and motor  impairment  seems to  vary depending 
on the type of  pain.  This  modal i ty  of  t reatment  was found to  
have a  maximal  effect  on dystonic  pain which character is t ical ly  
occurs  in  the Off  drug per iod.  This  correlated with improvement  
in  the qual i ty  of  l i fe . 11 Deep Brain St imulat ion of  the Globus 
Pal l idus Interna has  a lso been found to  be effect ive in  re l ieving 
pain in  Parkinson’s  Disease.  One s tudy showed improvement  in  
pain by 74% and dysesthesia  by 100% fol lowing uni la teral  
pal l idal  deep brain s t imulat ion.  On bi la teral  pal l idal  s t imulat ion 
,  th is  response was 90% for  pain and 88% for  dysesthesias .  
Pal l idotomy has a lso been found to  improve muscle  pain in  
pat ients  with Parkinson’s  Disease.  15 
I t  has  been demonstrated that  dopamine agonis ts  such as  
apomorphine have a  much lesser  effect  on pain,  compared to  
levodopa.  Rot igot ine has  been suggested as  an except ion to  this  
s ince i t  improved Liker t  pain scale  scores  in  the RECOVER 
study.15 
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Muscu loske le t a l  pa in can be managed wi th exe rc i se  and 
rehabi l i ta t ive programs to  correct  the gai t  and improve the 
funct ion of  axial  muscles ,  which are  the pr imari ly  affected 
muscles  in  Parkinson’s  Disease.   
Muscular  deformit ies  such as  s t r ia ta l  foot  and hand are  much 
less  responsive to  dopaminergic  medicat ion.  In  these s i tuat ions,  
baclofen,  ant ichol inergic  therapy and benzodiazepines  have 
been found to  be moderately successful .  Botul inum toxin is  
another  opt ion for  focal  dystonias . 15 
Neuropathic  pain can be managed s imilar  to  neuropathic  pain of  
any o the r  cause .  Du loxe t ine ,  a  s e l ec t ive se ro ton in and 
noradrenal ine reuptake inhibi tor,  is  found to  be effect ive.  
This  drug has  also been found to  be effect ive in  the central  pain 
syndrome of  Parkinson’s  Disease.  
Akathis ia  has  been found to  respond to  dopaminergic  drugs in  a  
few studies .  
Newer s t ra tegies  are  now under  development ,  which target  the 
descending inhibi tory pain control  pathways.  11 
The t reatment  of  disabl ing pain with analgesics  was reported in  
a  Bri t ish s tudy.12 Almost  half  the pat ients  suffer ing from 
intermit tent  pain did not  take any analgesics  owing to  the 
per iodic i ty  of  the symptom. However  taking into account  
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pat ients  suffer ing from higher  severi ty  of  pain or  pain which 
was interfer ing with act ivi t ies  of  dai ly  l iving,  this  number  
d ropped to  20%. Th i s  s t udy fu r the r  s t a t e s  t ha t  pa in i n  
Parkinson’s  Disease is  grossly undertreated.12 This  low number 
of  pat ients  taking analgesic  medicat ion could also be due to  a  
possibi l i ty  that  the pat ient  had taken analgesics  and found them 
to be ineffect ive and hence discont inued.  This  his tory is  usual ly  
missed unless  specif ical ly  asked for. 16  
A systematic  review of  s tudies  ,  52.4% of  the pat ients  used 
analgesic  medicat ion.  Non-opioid analgesics  were used by 
37.6%, weak or  s t rong opioids  by 13.5% and co-analgesics  by 
11.8%. The co-analgesics  used were mainly ant i -depressant  or  
ant i -convuls ive drugs. 16 
Along with the central  pain processing anomalies ,  t reatment  
should also be directed to  the loco-regional  factors ,  such as  
r i g i d i t y,  b r a d y k i n e s i a ,  o s t e o p o r o s i s ,  r h e u m a t i c  d i s e a s e ,  
degenerat ive disc  disease,  ar thr i t is  and disc  herniat ion,  which 
contr ibute  to  the development  of  pain in  the pain-predisposed 
condi t ion that  is  Parkinson’s  Disease. 17 
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MATERIALS AND METHODS 
SETTING 
The s tudy was conducted in  the Madras  Inst i tute  of  Neurology 
and the Inst i tute  of  Internal  Medicine,  Madras  Medical  Col lege 
and Raj iv  Gandhi  Government  General  Hospi ta l .  
ETHICS COMMITTEE APPROVAL 
The s tudy was approved by the Inst i tut ional  Ethics  Commit tee 
of  Madras  Medical  Col lege,  Chennai .  
STUDY DURATION 
This  s tudy was done between Apri l  2016 and August  2016.  
STUDY POPULATION 
Pat ients  with Parkinson’s  disease at tending the Movement  
Disorders  Cl inic ,  Madras  Inst i tute  of  Neurology and pat ients  
who were admit ted in  the Madras  Inst i tute  of  Neurology and the 
Inst i tute  of  Internal  Medicine,  Madras  Medical  Col lege and 
Raj iv  Gandhi  Government  General  Hospi ta l  were included in  
the s tudy.  
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TYPE OF STUDY 
Observat ional  s tudy 
SAMPLE SIZE 
51 pat ients  were recrui ted from the Movement  Disorders  Cl inic ,  
Madras  Inst i tute  of  Neurology and the Inst i tute  of  Internal  
Medicine,  Madras  Medical  Col lege and Raj iv  Gandhi  
Government  General  Hospi ta l .  
INCLUSION CRITERIA 
Pat ients  who were diagnosed with Parkinson’s  Disease 
according to  the UKPDS Brain bank cr i ter ia .  
EXCLUSION CRITERIA 
Pat ients  with a  diagnosis  of  any of  the fol lowing,  
1. Psychiatr ic  i l lness  
2. Per ipheral  Neuropathy 
3. Radiculopathy 
4. Recent  t rauma 
5. Parkinson Plus  syndromes 
6. Secondary Parkinsonism 
7. Osteoarthr i t is  
were excluded from the s tudy.  
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DATA COLLECTION AND METHODS 
51 Pat ients  diagnosed with Parkinson’s  Disease (as  def ined by 
U K P D S B r a i n b a n k g u i d e l i n e s )  w e r e r e c r u i t e d f r o m t h e 
Movement  Disorders  Cl inic ,  Madras  Inst i tute  of  Neurology and 
the Inst i tute  of  Internal  Medicine,  Madras  Medical  Col lege and 
Raj iv  Gandhi  Government  General  Hospi ta l .  
The pat ients  were informed of  the nature  of  the s tudy and 
informed consent  was obtained.  The pat ients  were categorised 
based on the durat ion and s tage of  the disease according to  
Hoehn and Yahr  s taging.  The exclusion cr i ter ia  were ruled out  
by his tory and cl inical  examinat ion.  The t reatment  his tory of  
each pat ient  was noted.  Each pat ient  was adminis tered a  
s t ructured quest ionnaire .  The quest ionnaire  was adminis tered in  
a  s tandardised manner  by the pr incipal  invest igator.  I t  included 
quest ions about  the presence or  absence of  pain,  a long with the 
character is t ics  and severi ty  of  the pain when present .  The 
severi ty  of  pain experienced by the pat ient  was graded on the 
Visual  Analog Scale .  The correlat ion of  the pain to  drug intake 
was also noted.  The quest ionnaire  adminis tered for  the purpose 
of  this  s tudy is  included in  the Annexure A.  
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The data  col lected was compiled and analysed using Excel  data  
analysis  sof tware.  
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RESULTS 
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RESULTS 
The total  number of  pat ients  diagnosed with Parkinson’s  disease 
who sat isf ied the inclusion and exclusion cr i ter ia  was 51.  Pain 
was seen in  33 pat ients  and absent  in  18.  
Demographic  character is t ics  of  the sample:  
Among the pat ients  included in  the sample,  there  were 35 males   
(69%) and 16 females  (31%).   
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Presence of pain
35%
65%
yes no
31%
69%
Male Female
The correlat ion between male sex and presence of  pain was 
calculated and the R value was-0.3225.  Although this  shows a  
negat ive correlat ion,  the relat ionship between the var iables  is  
weak and hence not  a  s ignif icant  f inding. 
The age of  the pat ients  included in  the sample ranged from 43 
years  of  age to  81 years  of  age (Mean= 64.31 years  ±9.25)  
Disease character is t ics  observed in  the sample:  
The average durat ion s ince onset  of  symptoms in  the sample 
was 5.71 years  (S.D.= ±4.11) .   
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The durat ion of  disease did not  have any s ignif icant  effect  on 
pain experienced by the pat ient .  The effect  of  durat ion of  the 
disease on the pain experienced by the pat ient  was not  found to  
be s ta t is t ical ly  s ignif icant .  (p= 0.4998) .  The correlat ion was 
R=0.3749 which was posi t ive but  not  s ta t is t ical ly  s ignif icant .  
Using the Hoehn and Yahr  s taging cr i ter ia ,  the  s tage of  the 
disease was determined for  a l l  the  pat ients  in  the sample based 
on the disease character is t ics .  There were 14 pat ients  in  s tage 4 
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Correlation of Duration and Pain
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(27.45%),  32 pat ients  in  s tage 3 (62.75%),  3  pat ients  in  s tage 2 
(5.88%) and 2 in  s tage 1 (3.92%).  
In  the sample s tudied,  33 pat ients  complained of  pain,  while  18 
did not .  
Local isat ion of  the pain:  
The locat ion of  the pain in  the sample s tudied was determined 
based on the quest ionnaire .  There were var ied responses .  The 
lower back was the most  common si te  of  pain (11) ,  fol lowed by 
lower l imbs (7) ,  diffuse pain (5) ,  neck and shoulders  (4) ,  upper  
l imbs (3) ,  girdle  (2)  and head (1) .  
Character  of  Pain:  
The pat ients  in  the sample complained of  a  var ied character  of  
pain.  Of the different  types,  cramping was the most  common 
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with 19 pat ients  complaining of  i t .  8  pat ients  complained of 
dul l  aching pain.  4  pat ients  complained of  burning type of  pain 
and 2 complained of  a  sharp pain.  
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The severi ty  of  the pain experienced by the pat ients  was 
determined using the Visual  Analog Scale .  The severi ty  ranged 
from VAS scores  of  2  to  10.  The sample was arbi t rar i ly  divided 
into mild,  moderate  or  severe pain based on cut-off  VAS scores  
of  5  and 8.  Mild pain was seen in  4  pat ients ,  moderate  pain in  
21 pat ients  and severe pain in  8  pat ients .  
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The t iming of  the pain was var ied among the sample s tudied.  
Most  commonly the pain was exer t ional ,  seen in  12 pat ients ,  
intermit tent  in  8  pat ients ,  nocturnal  pain was seen in  6  pat ients ,  
pain was occasional  in  6  pat ients  and pain remained pers is tent  
in  only 2 pat ients .  
A m o n g t h e p a t i e n t s  c o m p l a i n i n g o f  p a i n ,  2 0 h a d a n 
improvement  in  pain on ant iparkinsonian drug intake while  13 
had no response.  No pat ients  complained of  a  worsening of  pain 
on drug intake.  
Of the 51 pat ients  in  the sample,  38 did not  consume alcohol  or  
smoke tobacco.  Of those who reported pain,  4  consumed alcohol  
while  2  were smokers .  Of those without  pain 4 consumed 
alcohol  and 3 were tobacco smokers .   
The correlat ion between the use of  tobacco products  and/or  
a lcohol  and the presence of  pain was calculated.  The value of  R 
i s  -0 .0046.  Al though there  i s  a  negat ive corre la t ion ,  the 
relat ionship between the var iables  is  weak and hence not  a 
s ignif icant  f inding.  
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In  the sample s tudied,  comorbidi t ies  were seen in  37 of  the 51 
pat ients .  In  32 pat ients  i t  was not  associated with pain,  while  in  
the remaining 5 there  was presence of  pain.  
The correlat ion between the presence of  comorbidi t ies  and the 
presence of  pain was calculated.  The value of  R is  0 .3428.  
Al though there  i s  a  pos i t ive cor re la t ion ,  the re la t ionship 
between the var iables  is  weak and hence not  a  s ignif icant  
f inding.  
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Of the sample s tudied with the presence of  pain,  levodopa was 
taken in  a l l  of  them. 16 had decrease in  pain with drug intake 
while  11 had no change.  Among those taking ant ichol inergics ,  
12 had decrease in  pain and 8 had no change.  In  those on dopa 
agonis ts ,  pain decreased in  8  and there  was no change in  2 .  
However  there  were no pat ients  without  pain who were taking 
dopa agonis ts .  No pain-free individuals  were on s ingle-  drug 
regimen.  The correlat ion between the use of  levodopa ,  
ant ichol inergics  and dopa agonis ts  and the presence of  pain was 
calculated.  The R value for  levodopa was -0.2155.  For  
ant ichol inergics ,  R value was -0.2966.  Dopa agonis t  had R 
value of  0 .2437.  The relat ionship between the var iables  is  weak 
and hence not  a  s ignif icant  f inding.  
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There is  a  poor  posi t ive correlat ion of  R=0.0382 between 
durat ion of  disease and the presence of  pain.  This  is  not  
s ta t is t ical ly  s ignif icant .  
The correlat ion between the s tage of  Parkinson’s  Disease and 
presence of  pain was calculated.  The R value is  0 .0879 which 
showed a  weak correlat ion and is  not  s ta t is t ical ly  s ignif icant .  
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The correlat ion between the presence of  comorbidi t ies  and 
severi ty  of  pain was calculated.  The R value is  -0 .0247.  The R 
value for  correlat ion between smoking or  a lcohol  and severi ty  
of  pain was -0.0191.  This  was a  negat ive correlat ion,  but  not  
s ta t is t ical ly  s ignif icant .   
The correlat ion between the durat ion of  disease and the severi ty  
of  pain was s ta t is t ical ly  insignif icant  with a  R value of  0 .3749.  
This  was a  weak posi t ive relat ionship.  
The s taging of  disease also did not  have a  s ignif icant  
correlat ion with severi ty  of  disease.  The R value was 0.2632,  
which was a  weak posi t ive correlat ion.  
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Correlation of Stage of PD and Severity of 
Pain
0
2.5
5
7.5
10
Stage of PD Severity of Pain
The correlat ion of  severi ty  of  pain and use of  levodopa was not  
s ignif icant  with R value of  -0 .1646.  This  showed a  weak 
negat ive correlat ion.   
The s tage of  the of  the disease does not  have any s ignif icant  
effect  on the pain experienced by the pat ient .  I t  was found to  be 
s ta t is t ical ly  insignif icant .  (p=0.499)  
The s tage of  the disease does not  have any s ignif icant  effect  on 
the severi ty  of  pain experienced by the pat ient .  The effect  of  
the s tage of  disease on severi ty  of  pain was s ta t is t ical ly  
insignif icant .  (p=0.499)  
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Correlation of Duration of PD and Severity 
of Pain
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The durat ion of  disease does not  have a  s ignif icant  effect  on the 
severi ty  of  pain experienced by the pat ient .  The effect  was 
s ta t is t ical ly  insignif icant . (p=0.3424)  
There was no s ignif icant  effect  of  the drug intake on pain based 
on the type of  pain experienced.  (p=0.4295)  
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Correlation of type of Pain and response to Drug intake
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Correlation with drug intake
There was no s ignif icant  effect  of  the type of  pain on the 
locat ion of  pain experienced by the pat ient .  (p=0.4648)
The type of  pain experienced did not  have a  s ignif icant  effect  
on the severi ty  of  the pain experienced.  p=0.4819 
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DISCUSSION 
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The s tudy was done on a  small  sample of  51 pat ients .  The s tudy 
showed a  prevalence of  pain of  68.62%. This  was s imilar  to  
previous s tudies  which had demonstrated a  prevalence of  
40-80%. The prevalence in  women was 87.5% and in  men was 
54.28%. This  was in  keeping with previous s tudies  which has  
postulated female sex as  a  r isk factor  for  pain.  However  the 
correlat ion between the sex of  the pat ient  and the presence of  
pain was s ta t is t ical ly  s ignif icant .  
The most  common locat ion of  the pain was the lower back,  
which was  
in  contrast  to  pre-exis t ing s tudies  which had reported lower 
l imb pain as  the most  common.  
Most  of  the pat ients  complained of  a  moderate  severi ty  of  pain 
with very few complaining of  high severi ty.  
The moat  common type of  pain was cramping,  musculoskeletal  
pain.  This  was again the same as  reported in  previous s tudies .  
The musculoskeletal  pain was most  common in the lower back.  
Central  type of  pain was seen most  commonly in  the lower 
l imbs.  Radicular  pain was reported only in  the lower back.  
Akathis ia  and dystonic  pain was not  reported by any of  the 
pat ients .  
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The most  common t iming of  the pain was on exert ion.  Pers is tent  
pain was very rarely seen.  Pat ients  reported an improvement  in  
the pain on ant i -parkinsonian drug intake.  I t  was seen in  60.6% 
of  pain while  the rest  of  the pat ients  had no change on drug 
intake.  No pat ients  complain of  a  worsening of  pain on drug 
intake.  This  correlates  with the f inding that  there  was no 
reported dystonic  pain.   
The s tudy showed a  weak posi t ive correlat ion between the 
presence of  comorbidi t ies  and the presence of  pain.  This  needs 
to  be val idated using a  larger  sample s ize .   
The use of  levodopa had a  weak negat ive correlat ion with the 
presence of  pain,  without  s ta t is t ical  s ignif icance.  This  was 
s imilar  to  previous s tudies  which showed a  decreased 
prevalence of  spontaneous pain on levodopa use.  
A s imilar  effect  was seen with ant ichol inergic  use.  However  
dopamine agonis t  had a  weak posi t ive correlat ion to  presence of  
pain.  This  suggests  a  possible  different  mechanism of  act ion for  
levodopa for  decreasing pain.  
The durat ion of  the Parkinson’s  Disease showed a  weak posi t ive 
correlat ion with the severi ty  of  pain experienced.  This  suggests  
that  pain can be par t  of  the natural  his tory of  the his tory with 
the spread of  the disease pathology to  areas  of  pain processing.  
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This  is  a lso ref lected in  the weak posi t ive correlat ion between 
the s tage of  the disease with the severi ty  of  pain.  
 Use of  levodopa has  a  negat ive correlat ion with the severi ty  of  
pain but  i t  was not  s ta t is t ical ly  s ignif icant .  This  probably 
ref lects  the small  s ize  of  the sample in  the s tudy and needs 
more work to  be cl inical ly  val idated.   
Conversely,  use of  dopa agonis ts  was associated with a  higher  
sever i ty  of  pain.  However  the correlat ion was weak and not  
s ta t is t ical ly  s ignif icant .  
In  pat ients  with pain,  the use of  dopa agonis ts  showed a  more 
frequent  improvement  in  pain on drug intake.  However  the 
correlat ion is  not  s ta t is t ical ly  s ignif icant .   
Taking both these f indings into considerat ion,  there  is  a  
possibi l i ty  that  dopamine agonis t  use has  bet ter  effect  on 
control  of  pain than other  drugs.  However  this  needs to  be 
val idated in  fur ther  s tudies .  
The type of  pain correlated bet ter  with response to  drugs.  This  
is  probably due to  the effect  of  drugs on r igidi ty  and s t i ffness ,  
which can improve the musculoskeletal  pain in  these pat ients .  
LIMITATIONS OF THE STUDY: 
1. The s ize  of  the sample is  small   
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2. The data  col lect ion was from a s ingle  centre  
3. The classif icat ion and severi ty  of  pain were both subject ive 
and highly arbi t rary 
4. No object ive measures  were used  
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CONCLUSION 
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In  Parkinson’s  Disease,  the presence of  pain is  much more 
common than is  widely known.  The pain is  more common in the 
female populat ion and is  most  commonly of  the 
musculocutaneous type with moderate  severi ty  and located in  
the lower back.   
The presence of  pain seems to  depend on other  comorbidi t ies  
and absence of  a lcohol  or  smoking.  Dopamine agonis t  seems to  
be associated with a  higher  prevalence as  wel l  as  severi ty  of  
pain.  This  seems to  point  to  a  possible  causal  re la t ionship.   
The presence of  pain did not  correlate  with the durat ion and 
severi ty  of  pain however  the severi ty  of  pain was.  This  suggests  
that  the progression of  disease increases  the pain only in  those 
in  whom i t  is  a l ready present .  
This  s tudy did not  look at  the effect  of  pain on the qual i ty  of  
l i fe  in  pat ients  with Parkinson’s  Disease.   
The effect  of  drugs on pain threshold could not  be rel iably 
tes ted due to  the absence of  object ive tes t ing in  the s tudy.  
There is  evidence that  drug intake pr imari ly  improves the 
musculoskeletal  pain rather  than other  types of  pain.   
This  s tudy was l imited by the s ize  of  the sample.  The absence 
of  an object ive tes t ing of  pain threshold also l imited the scope 
of  the s tudy.  Further  s tudies  with larger  sample s izes  and use of  
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object ive tes t ing systems along with detai led scoring scales  to  
col lect  more data  regarding related data  such as  non-motor  
complicat ions of  pain,  are  needed.  
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ANNEXURES 
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ABBREVIATIONS 
PD                   - Parkinson’s Disease 
VAS                 - Visual Analog Scale 
SSR                 - Sympathetic Skin Response 
LEP                 - Laser Evoked Brain Potentials 
NFR                 - Nociceptive Flexion Response 
PET                  - Positron Emission Tomography 
MRI                 - Magnetic Resonance Imaging 
UKPDS            - United Kingdom Parkinson’s Disease Society 
MDS                - Movement Disorder Society 
HY                  - Hoehn and Yahr Staging system 
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PROFORMA 
NAME OF THE PATIENT : 
AGE / SEX    : 
IP/OP NUMBER   : 
OCCUPATION   : 
ADDRESS    : 
CONTACT NUMBER  : 
CARE GIVER                            : 
PAST HISTORY   :     Diabetes mellitus: 
           Systemic hypertension: 
           Chronic Kidney Disease 
           Others: 
TREATMENT HISTORY:                                                                                        
PERSONAL HISTORY :  Smoking :    
                                           Alcohol: 
     Other substance abuse: 
CLASS OF DRUG WHETHER TAKEN
 Levodopa 
 Anticholinergics
Dopamine agonist
MAO-B inhibitors
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DURATION OF PARKINSON’S DISEASE: 
STAGING OF PARKINSON’S DISEASE: 
PRESENCE OF PAIN : 
LOCATION OF PAIN : Head and neck 
                                       Upper limbs- Proximal 
                                                             Distal 
                                       Lower Limbs- Proximal 
                                                               Distal 
                                      Trunk- Chest 
                                                  Abdomen 
                                                  Groin 
                                       
                                      Back- Upper 
                                                Lower 
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TYPE OF PAIN : Sharp/Shooting 
                             Dull aching 
                             Burnished  
                             Cramping 
SEVERITY OF PAIN:  
TIMING OF PAIN:    Persistent 
                                   Intermittent 
                                   Occasional 
                                   Diurnal variation 
CORRELATION WITH DRUG INTAKE: Increased 
                                                                     Decreased 
                                                                     No change 
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INFORMATION SHEET                                                                                                                                                                                                                                                                                                                                                                                                    
We are conducting a study on  “PREVALENCE AND SPECTRUM OF 
PAIN IN PARKINSON’S DISEASE” among patients attending Rajiv 
Gandhi Government General Hospital, Chennai  
The purpose of this study is to assess “PREVALENCE AND 
SPECTRUM OF PAIN IN PARKINSON’S DISEASE” 
We are selecting certain cases and if you are found eligible, we 
may be using clinical profile, lab test reports and radiological reports for 
study purposes which does not affect your final report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
Signature of Investigator 
Date: 
Place: 
Signature of Participant / 
Guardian 
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PATIENT CONSENT FORM 
Patient may check (☑) these boxes 
Signature of Investigator     Signature/thumb impression 
Study Investigator’s Name:   Patient’s Name and Address: 
Study Detail : PREVALENCE AND SPECTRUM OF PAIN IN 
PARKINSON’S DISEASE
Study Centre : Rajiv Gandhi Government General Hospital, Chennai.
Patient’s Name :
Patient’s Age :
Identification 
Number
:
The details of the study have been provided to me in writing and explained to 
me in my own language ❏
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights 
being affected. ❏
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory 
authorities will not need my permission to look at my health records, 
both in respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree 
to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. ❏
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏
I hereby consent to participate in this study. ❏
I hereby give permission to undergo complete clinical examination , 
biochemical and radiological tests ❏
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